A randomized controlled trial for beta agonist on ulolithiasis patients associated with overactive bladder.

A randomized controlled trial for beta agonist on ulolithiasis patients associated with overactive bladder. - A randomized controlled trial for beta agonist on ulolithiasis patients associated with overactive bladder.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010553

Enrollment

100

Registered

2013-05-01

Start date

2013-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urolithiasis

Interventions

Mirabegron Tolterodine tartrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients diagnosed as urolithiasis 2) patients associated with overactive bladder 3) Age; 20<= 4) ECOG performance status 0-1 5) Patiens have enough organ function 6) able to take mirabegron by mouth 7) agreement to sign an informed consent 8) on blood test 1.WBC>=3,000-<=12,000/mm3, 2.Neurtophils>=1,500/mm3 3. Platelets>=100,000/mm3 4. AST / ALT: not more than twice baseline 5. Total bilirubin<=3.0mg/dl 6. Hemoglobin>=9.0g/dl 8. Creatinine<= 2.0mg/dl

Exclusion criteria

Exclusion criteria: 1) patients already receiving beta agonists 2) patients addicted to alcohol or drugs 3) contraindications cases of experimental drugs 4) pregnant or lactating women 5) individuals who are diagnosed as inappropriate for the trial.

Design outcomes

Primary

Measure	Time frame
Stone free ratio after administration of drugs	—

Countries

Japan

Contacts

Public ContactHiroshi Hongo

Isehara Kyodo Hospital Department of Urology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026